34 results about "Verapamilum" patented technology

The invention provides a method and kit for guiding administration of verapamil by simultaneously detecting multiple loci related to the metabolism of the antihypertensive drug verapamil through matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) because different single nucleotide polymorphism (SNP) loci have extension primers with different molecular weights. The method includes the following steps: designing multiple amplification primers and extension primers according to eight target SNP loci to be detected; preparing a multiple amplification primerreaction system and an extension primer reaction system; in the reaction systems, simultaneously performing amplification and single-base extension reactions on the eight target SNP loci by using multiple sets of primers; and performing time-of-flight mass spectrometry analysis on the products after the single-base extension reactions, and identifying the genotypes of different drug metabolism-related SNP loci according to the products of different-molecular-weight extension primers represented by mass spectrum peaks to guide the administration of the antihypertensive drug verapamil. At the same time, the invention provides the detection kit using the method. The method can simultaneously detect the eight SNP loci related to the metabolism of the antihypertensive drug verapamil, and has the advantages of low costs, no need for synthesis of probes, short time consumption, simple and convenient result analysis, and extremely wide application fields.

The invention discloses verapamil liposome and a preparation method of the verapamil liposome, belonging to the technical field of medicine. The verapamil liposome is composed of verapamil, phospholipid, cholesterol, chitosan, cationic lipid and antioxidant, etc., all of which are in certain weight percentage. The verapamil liposome is prepared by adopting ammonium sulphate gradients method, filmhydration method, ethanol injection method and reverse phase evaporation method. The invention adopts chitosan or derivatives of the chitosan to modify the surface of the liposome, and applies the chitosan to ophthalmic preparation, which can further increase corneal retention of the liposome and can remarkably improve the corneal penetration amount of the drug, with obvious advantages compared with ordinary liposome. With high entrapment efficiency, good stability, good biocompatibility, biological adhesiveness and biodegradability, the prepared liposome can realize sustained release and long-acting administration, particularly suitable for administration on ocular region, and can better play the ocular effects of anti-glaucoma and anti-cataract of verapamil.

The invention provides a primer combination for differentiating verapamil individualized medication types. An extension primer which has different molecular weights at different single nucleotide polymorphism (SNP) sites is utilized, so that through matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), a plurality of sites pertinent to metabolism of a hypertension reducing medicine namely verapamil can be detected at the same time, and finally the primer combination for differentiating verapamil individualized medication types is obtained. A preparation method of the primer combination comprises the steps of according to 8 objective SNP sites to be detected, respectively designing a multiplex amplification primer and an extension primer; compounding amultiplex amplification primer reaction system and an extension primer reaction system; in the reaction systems, performing amplification and a single-base extension reaction on the 8 objective SNP sites at the same time with multiple sets of primers; and performing time-of-flight mass spectrometry analysis on products after the single-base extension reaction, identifying the genotypes of different drug metabolism pertinent SNPs according to products of different molecular weight extension primers represented by mass spectrum peaks, and guiding the medication of the hypertension reducing medicine namely the verapamil. The primer combination disclosed by the invention can detect 8 metabolism pertinent SNP sites of the hypertension reducing medicine namely the verapamil at the same time, and has the advantages of being low in cost, free from synthetized probes, short in time consumption, simple and convenient in result analysis, and extremely broad in application field.

The present invention relates to the application of marine phospholipids as active ingredients in the preparation of drugs for the prevention and / or treatment of heart diseases. The present invention separates and obtains five phospholipid components including phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine , sphingomyelin, the present invention finds that the above components have better protective and therapeutic effects on the heart; zebrafish thrombus induced by arachidonic acid, zebrafish heart failure induced by verapamil and terfenadine induced Zebrafish arrhythmia, phospholipid components show a significant cardioprotective effect, can significantly reduce zebrafish congestion, heart dilation and promote heart rate tends to normal.

The invention provides a temperature-sensitive sustained-release preparation of verapamil, comprising: drug-loaded denatured albumin, multilamellar liposome (SUV) and thermosensitive glue; wherein the drug-loaded denatured albumin includes denatured albumin and an effective amount of verapamil. The present invention also provides a preparation method and application of the above-mentioned verapamil temperature-sensitive sustained-release preparation. The above preparation adopts denaturation of human serum albumin and incubates with verapamil to absorb verapamil to form drug nanoparticles, encapsulates albumin-verapamil drug nanoparticles with small unilamellar liposomes, and finally mixes with thermosensitive preparation Loxamer 127 is mixed to form a three-phase sustained-release system of drug-loaded albumin nanoparticles-multilamellar liposomes-thermosensitive adhesive.

The invention provides a method for discriminating individualized verapamil medication by mass spectrometry through a primer composition. The method comprises the following steps: respectively designing multiple amplification primers and extension primers according to eight to-be-detected target SNP loci; preparing a multiplex amplification primer reaction system and an extension primer reaction system; in the reaction systems, simultaneously and respectively carrying out amplification and single-base extension reaction on the eight target SNP loci by using a plurality of sets of primers; andcarrying out time-of-flight mass spectrometry analysis on a product after the single base extension reaction, identifying genotypes of SNP related to different drug metabolism according to products ofextension primers with different molecular weights represented by a mass spectrum peak, and guiding the medication of hypotensive drug verapamil. The method can simultaneously detect eight SNP loci related to metabolism of the hypotensive drug verapamil, and has the advantages of low cost, no need of probe synthesis, short time consumption, simple and convenient result analysis and extremely wideapplication field.

The invention belongs to the field of chemotherapeutic drug sensitivity enhancing medicine and particularly relates to use of a hematoporphyrin-verapamil-fragment-combined hematoporphyrin derivative A2 in tolerance and sensitivity enhancing of stomach cancer reversing chemotherapeutic drugs. The hematoporphyrin derivative A2 has different extents of chemotherapeutic-drug-sensitivity-enhanced stomach cancer cell proliferation inhibiting actions, and it is shown that the hematoporphyrin derivative A2 can be developed into chemotherapeutic-drug sensitizing agents or drug resistance reversing agents and is applied to treatment on stomach cancer sufferers.

The invention provides a Verapamil Hydrochloride sustained release capsule; the weighting materials in the capsule are micropills; the micropill comprises a pill-containing core, an expansion layer and a controlled release layer from the interior to the exterior in turn; the weight of the pill-containing core accounts for 58 to 68 percent of the weight of the micropills; the expansion layer accounts for the 8 to 18 percent of the weight of the micropills; the controlled release layer accounts for 18 to 28 percent of the weight of the micropills; the Verapamil Hydrochloride sustained release capsule is a sustained release medicament-release system; the system can provide 4 to 6 hours of time lag and then slowly releases the medicament; more constant blood medicine concentration is maintained in a period of time; moreover, the preparation process of the capsule is simple and short; the production cost is lower; moreover, the Verapamil Hydrochloride sustained release capsule is beneficial to large industrial production.

The invention discloses a method for building P-glycoprotein (P-gp) research models based on human small intestine 3D (three-dimensional) organoid. The method includes inoculating human small intestine crypts in matrigel at first, adding ADMEM / F12 culture media with specific growth factors into the matrigel and cultivating the human small intestine crypts to form 3D organoids; carrying out morphological observation and detecting expression of P-gp from mRNA [messenger RNA (ribonucleic acid)] and protein level; researching influence of Verapamil and Mitotane on Rh123 transportation by the aid of a co-incubation process by Rhodamine 123 (Rh123) which is used as a substrate. The method has the advantages that the P-glycoprotein research models based on human small intestine 3D organoid can be applied to P-gp-mediated medicine transport research and also can be widely applied to in-vitro high-throughput screening on P-gp inhibitors, and the method is high in efficiency and speed.